From bench to bedside
The emerging scientific discipline of translational medicine bridges the gap between fundamental research carried out in laboratories and clinical research carried out on patients.
The aim is to have laboratories, practitioners and patients working closely together to make new treatments - cancer treatments in particular - available as quickly as possible.
Committing to the realization of the Oncopole project in Toulouse at the turn of the millennium, with its campus housing researchers, clinicians, practitioners and patients on the same site, Pierre Fabre Laboratories took an interest in translational medicine very early on. Everything is now up and running. The Pierre Fabre Research Center is just over the road from the Toulouse University Cancer Institute - Oncopole (IUCT-O). The IUCT-O clinic receives 10,000 patients a year and is the first French treatment establishment to be awarded ISO 9001 certification for its management of cancer treatment clinical trials.
In 2016, the Group formed a partnership with the Toulouse Cancer Health Foundation and the French Institute of Health and Medical Research (INSERM), a translational medicine research chair focusing on immuno-oncology. With the support of the IUCT-O and integrated within the Toulouse Cancer Research Center (an INSERM structure), the chair will be managed by a doctor-researcher of international renown, for whom a recruitment drive was launched in June 2016.